Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Rexlemestrocel-L by Mesoblast for Hypoplastic Left Heart Syndrome: Likelihood of Approval
Rexlemestrocel-L is under clinical development by Mesoblast and currently in Phase II for Hypoplastic Left Heart Syndrome. According to GlobalData,...
Data Insights
Rexlemestrocel-L by Mesoblast for Congestive Heart Failure (Heart Failure): Likelihood of Approval
Rexlemestrocel-L is under clinical development by Mesoblast and currently in Phase III for Congestive Heart Failure (Heart Failure). According to...